Indian Journal of Paediatric Dermatology

ORIGINAL ARTICLE
Year
: 2021  |  Volume : 22  |  Issue : 2  |  Page : 123--130

A comparative study in treatment of childhood vitiligo 0.03% tacrolimus versus 0.03% tacrolimus and topical steroids


Anandan Venkatesan1, Rashmi Sriram2, Sindhuja Balaji3, TK Anandhi4 
1 Department of Dermatology, Government Stanley Medical College, Chennai, India
2 Department of Dermatology, BGS Global Institute of Medical Sciences, Bengaluru, Karnataka, India
3 Department of Dermatology, Chengalpattu Medical College, Chengalpattu, Tamil Nadu, India
4 Consultant Dermatologist, Everglow Dermacare Centre, Kanchipuram, Tamil Nadu, India

Correspondence Address:
Rashmi Sriram
BGS Global Hospital, No 67, BGS Health and Education City, Uttarahalli Road, Kengeri, Bengaluru - 560 060, Karnataka
India

Background: Vitiligo is an idiopathic, acquired cutaneous achromia, characterized by circumscribed milky white macules. It develops before the age of 20 years in 50% of the patients and before the age of 10 years in 25% of the patients. Methods: This was a 2-year, prospective, comparative study conducted in vitiligo patients with 1 year of active intervention. Fifty patients in the age group of 2–14 years were enrolled in the study. Randomization was performed according to computer-generated random code. Patients with code A received treatment with 0.03% tacrolimus alone and patients with code B received treatment with 0.03% tacrolimus and topical steroids. The primary efficacy variable was the Vitiligo Area Severity Index (VASI), and the secondary efficacy parameter includes the Physician's Global Improvement Score which was computed at the end of the study. The statistical analysis was carried out using statistical software STATA 6.0. Results: Out of these 50 patients, 47 patients completed the study for a period of 1 year. The area-wise VASI reduction and VASI reduction in vitiligo types were analyzed in patients with code A and code B. The mean Physician's Global Assessment Score was 3.041 in the tacrolimus group, and it was 3.261 in the tacrolimus with steroid group. Conclusion: This shows that 0.03% tacrolimus can be effectively used as topical monotherapy in patients with localized stable vitiligo without the adverse effects of topical steroids.


How to cite this article:
Venkatesan A, Sriram R, Balaji S, Anandhi T K. A comparative study in treatment of childhood vitiligo 0.03% tacrolimus versus 0.03% tacrolimus and topical steroids.Indian J Paediatr Dermatol 2021;22:123-130


How to cite this URL:
Venkatesan A, Sriram R, Balaji S, Anandhi T K. A comparative study in treatment of childhood vitiligo 0.03% tacrolimus versus 0.03% tacrolimus and topical steroids. Indian J Paediatr Dermatol [serial online] 2021 [cited 2021 Apr 18 ];22:123-130
Available from: https://www.ijpd.in/article.asp?issn=2319-7250;year=2021;volume=22;issue=2;spage=123;epage=130;aulast=Venkatesan;type=0